Form 8-K - Current report:
SEC Accession No. 0001829126-26-007760
Filing Date
2026-07-23
Accepted
2026-07-22 20:13:48
Documents
14
Period of Report
2026-07-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalabio_8k.htm   iXBRL 8-K 37312
2 EXHIBIT 5.1 kalabio_ex5-1.htm EX-5.1 17525
6 GRAPHIC ex5-1_001.jpg GRAPHIC 4398
7 GRAPHIC ex5-1_002.jpg GRAPHIC 1948
  Complete submission text file 0001829126-26-007760.txt   231504

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kala-20260722.xsd EX-101.SCH 2990
4 XBRL LABEL FILE kala-20260722_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE kala-20260722_pre.xml EX-101.PRE 22342
17 EXTRACTED XBRL INSTANCE DOCUMENT kalabio_8k_htm.xml XML 3095
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 261194877
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)